WebNews
Please enter a web search for web results.
NewsWeb
Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update
6+ mon, 4+ day ago (120+ words) FDA Fast Track Designation received for Allo NK in refractory RA, representing the first drug candidate in the deep B-cell depleting category to receive this designation with the potential to become the first in the category to advance to a…...
U. S. Physical Therapy Announces $450 Million Credit Facility
5+ day, 21+ hour ago (151+ words) The credit facility syndicate consists of Bank of America Securities Inc. as Joint Lead Arranger and Sole Bookrunner with Bank of America, N. A. as Administrative Agent, and Regions Capital Markets, a division of Regions Bank, as Joint Lead Arranger and Syndication…...
AJOVY" (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicine
3+ mon, 6+ day ago (290+ words) The 3-month, randomized, placebo-controlled SPACE study enrolled 237 children and adolescents aged 6-17 years with episodic migraine. Participants were randomized to receive monthly subcutaneous injections of fremanezumab (120 mg for those weighing Migraine attacks cause disabling pain, nausea, vomiting and sensitivities to light…...
Abb Vie Reports Positive Topline Results From Phase 3 TEMPLE Study Of Atogepant For Migraine
10+ mon, 3+ day ago (118+ words) (RTTNews) - Biopharmaceutical company Abb Vie, Inc. (ABBV) announced Wednesday positive topline results from its Phase 3 TEMPLE multicenter, randomized, double-blind, head-to-head study evaluating the tolerability, safety and efficacy of atogepant (QULIPTA/AQUIPTA, 60 mg once dail | June 18, 2025 " 07: 45 am EDT Over the 24-week…...
Abb Vie Announces New Data Demonstrating Atogepant (QULIPTA" / AQUIPTA") Achieves Superiority Across All Endpoints in Phase 3 Head-to-Head Study Compared to Topiramate for Migraine Prevention
10+ mon, 3+ day ago (54+ words) --Abb Vie today announced positive topline results from its Phase 3 TEMPLE multicenter, randomized, double-blind, head-to-head study evaluating the tolerability, safety and efficacy of atogepant compared to the highest tolerated dose of topiramate in adult patients with a history of four…...
Organogenesis Initiates BLA Submission For Re Nu In Knee Arthritis
3+ mon, 4+ week ago (312+ words) December 24, 2025 " 02: 21 am EST (RTTNews) - Organogenesis Holdings Inc. (ORGO), a regenerative medicine company announced that it has initiated the submission of a Biologics License Application or BLA to the US Food and Drug Administration or FDA for its lead amniotic suspension…...
Aurora Spine Launches New Biologics Portfolio
5+ mon, 3+ week ago (285+ words) CARLSBAD, CA, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (Aurora Spine) (TSXV: ASG) (OTCQB: ASAPF), a leader in minimally invasive spine and interventional pain solutions, today announced the launch of Aurora Biologics, a new division dedicated to advancing spinal fusion success…...
Raphael Pharmaceutical Announces Filing of Provisional Patent Application for the Treatment of Neutrophil-Dominant Autoimmune Diseases, Including Rheumatoid Arthritis (RA)
5+ mon, 4+ day ago (391+ words) NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Raphael Pharmaceutical Inc. (Raphael Pharmaceutical" or the Company") (OTCQB: RAPH), a clinical-stage biotechnology company developing an innovative research platform based on cannabinoids free of THC and CBD, today announced the filing of a provisional patent…...
CBD Life Sciences Inc. (CBDL) Releases New CBD Suppositories for Vaginal & Rectal Relief
10+ mon, 2+ week ago (333+ words) CBDL Enters the $2. 8 Billion Suppository Market with a First-of-Its-Kind Product - Tapping a High-Demand, Low-Competition Sector Poised for Transformational Growth A Breakthrough for Localized, Fast-Acting Relief Unlike oral CBD products, which must pass through the digestive system and may lose potency…...
Bio Cor Rx, Inc. Announces Initiation of Clinical Study by Majority-Owned Subsidiary Bio Cor Rx Pharmaceuticals, Inc. Evaluating Long-Acting Naltrexone Implant With or Without Bupropion
3+ mon, 1+ week ago (248+ words) Clinical Study Evaluating a Long-Acting Naltrexone Implant Under the FDA's 505(b)(2) Pathway" The study: Safety and Pharmacokinetics Study of BICX104 With or Without Bupropion Compared to Vivitrol (Clinical Trials. gov Identifier: NCT07269873) is now underway following completion of required institutional review requirements. The…...